Is Diclofenac a Controlled Substance or Narcotic?

Diclofenac is not a controlled substance, and it is not a narcotic. It belongs to the nonsteroidal anti-inflammatory drug (NSAID) class, the same family as ibuprofen and naproxen. No government scheduling agency in the United States, the European Union, or any other major jurisdiction lists diclofenac alongside opioids, benzodiazepines, or other controlled medications. The confusion is understandable, though, because diclofenac is a potent painkiller that often requires a prescription, and its strength sometimes surprises people who associate “real” pain relief only with narcotics.

Why the Confusion Exists

Several things about diclofenac make people wonder whether it sits in a more restricted category than it actually does. First, many oral and injectable forms of diclofenac are prescription-only in the United States and much of Europe, which gives it an air of being something more tightly regulated. Over-the-counter painkillers feel familiar and mild; anything that needs a doctor’s signature can seem stronger or more dangerous by association. Second, diclofenac is genuinely effective for moderate-to-severe pain, and patients recovering from surgery or living with arthritis sometimes receive it alongside opioids, which can blur the lines. Third, the word “narcotic” has drifted in popular usage. Technically it refers to opioid drugs that act on specific receptors in the brain, but people often use it loosely to mean any strong prescription painkiller. Diclofenac is strong, and it is a painkiller, but it works through an entirely different mechanism.

How Diclofenac Actually Works

Narcotics, or opioids, relieve pain by binding to opioid receptors in the brain and spinal cord, which is also why they cause sedation, euphoria, respiratory depression, and physical dependence. Diclofenac does none of that. It works by blocking cyclooxygenase enzymes, known as COX-1 and COX-2, with roughly equal potency against both forms.¹ These enzymes produce prostaglandins, chemicals your body releases at injury sites that trigger inflammation, swelling, and pain signaling. By dialing down prostaglandin production, diclofenac reduces inflammation at the source rather than masking the pain signal in the brain.

There is also evidence that NSAIDs like diclofenac have additional pain-relieving actions beyond prostaglandin suppression, including effects within the central nervous system that may involve interactions with serotonin pathways and other signaling molecules.² But none of these mechanisms involve opioid receptors, which is the key distinction. Diclofenac does not produce a “high,” does not cause the kind of physical dependence associated with narcotics, and does not carry any risk of the respiratory depression that makes opioid overdoses fatal.

Diclofenac Versus Opioids for Pain

One reason people are surprised diclofenac is “just” an NSAID is that head-to-head comparisons with opioids often show it performing remarkably well. A systematic review looking at knee osteoarthritis found that NSAIDs and opioids produced similar overall pain reductions once you accounted for people dropping out of studies due to side effects.³ A large network meta-analysis published in the BMJ went further, finding that oral diclofenac at 150 mg per day had a very high probability of producing clinically meaningful pain relief for knee and hip osteoarthritis, while all opioid preparations had a roughly coin-flip chance or worse of clearing that same threshold.⁴

That same analysis highlighted a dramatic difference in tolerability. None of the topical NSAID preparations showed an increased risk of side-effect-related dropouts, while roughly five out of six opioid preparations did. The worst offenders among opioids had dropout rates above 50 percent due to adverse events.⁴ So diclofenac is not just “as good” as opioids for certain conditions; in some contexts it delivers better pain control with fewer intolerable side effects. The catch is that diclofenac has its own set of serious risks, which are different from opioid risks but real.

The Opioid-Sparing Role

One of the most practical reasons clinicians value diclofenac is that it can substantially reduce how much opioid medication a patient needs after surgery. In a trial of patients recovering from coronary artery bypass grafting, those given diclofenac alone used about 40 percent less morphine over 24 hours than patients on placebo, and those given diclofenac combined with paracetamol (acetaminophen) used roughly two-thirds less.⁵ The patients who needed less morphine were extubated faster and had better oxygen levels, concrete benefits that come from not being sedated by high opioid doses.

Similar patterns show up in orthopedic surgery. After knee replacement, patients receiving diclofenac consumed significantly less oxycodone on the second and third postoperative days compared to placebo, and they reported lower pain scores during the treatment period.⁶ After abdominal surgery, total morphine consumption dropped by about a third when diclofenac was added to the pain regimen.⁷ This opioid-sparing ability is a big part of why diclofenac gets prescribed in contexts that people associate with narcotics. You might wake up from surgery receiving both diclofenac and morphine, and it is natural to assume both must be in the same drug class. They are not. The diclofenac is there specifically so you need less of the morphine.

Topical Versus Oral Forms

Diclofenac comes in a wide range of formulations, and the distinction between topical and oral matters more than most people realize. The gel and patch forms that you rub on or stick to a sore joint deliver the drug locally with dramatically less entering your bloodstream. In one study comparing topical diclofenac gel to oral diclofenac tablets in healthy volunteers, systemic exposure from the gel was five to seventeen times lower than from the oral form.⁸ A separate crossover study found even larger gaps, with oral diclofenac producing peak blood levels over 80 times higher than the topical gel applied to knees.⁹

This difference has practical implications. The topical gel did not inhibit platelet aggregation, and it suppressed COX-1 and COX-2 far less than oral diclofenac.⁸ That means many of the systemic risks people worry about with diclofenac are largely a concern with oral or injectable forms, not with the gel you apply to your knee. In many countries, topical diclofenac is available over the counter while the oral version remains prescription-only, a regulatory split that reflects the different risk profiles.

The Real Risks of Diclofenac

Diclofenac may not carry the addiction and overdose risks of opioids, but it does come with its own serious concerns, particularly for the heart. A large Danish population study found that people who started taking diclofenac had about a 50 percent higher rate of major cardiovascular events compared to non-users, including a roughly doubled rate of heart attack and cardiac death.¹⁰ A follow-up target trial emulation using nearly two million diclofenac users confirmed a similar magnitude of increased risk for heart attack, stroke, and cardiac death.¹¹

The cardiovascular picture has some counterintuitive wrinkles. A review of the coronary risk data noted that the elevated risk appeared most clearly in otherwise healthy, low-risk individuals, while in patients who already had high cardiovascular risk, diclofenac did not seem to add further danger beyond what other NSAIDs posed.¹² The authors of that review raised the possibility that confounding and biases in observational data could partly explain the small increases seen in healthy users. Still, the European Medicines Agency took the cardiovascular signal seriously enough to implement new contraindications and warnings for systemic diclofenac across the EU in 2013, restricting its use in people with established heart disease, stroke, or peripheral artery disease.¹³

Beyond the heart, diclofenac shares the gastrointestinal and kidney risks common to all NSAIDs. Animal studies have demonstrated that diclofenac can cause kidney tubular damage, gastrointestinal lesions, and liver function abnormalities, mediated in part by oxidative stress.¹⁴ In humans, the risk of stomach ulcers and bleeding increases with higher doses and longer use, which is one reason doctors emphasize using the lowest effective dose for the shortest period necessary.

Why It Is Not Scheduled

Drug scheduling systems like the US Controlled Substances Act exist to regulate drugs with abuse potential. A substance lands on the schedule based primarily on three factors: whether it produces psychoactive effects that people seek recreationally, whether it causes physical or psychological dependence, and whether it has accepted medical use. Opioids check all the concerning boxes. Diclofenac checks none of them. It does not produce euphoria. It does not create physical dependence where stopping abruptly causes withdrawal symptoms. Nobody takes diclofenac recreationally. There is no black market for it and no pattern of diversion from pharmacies.

A large real-world database study of over half a million people prescribed topical diclofenac gel in the US tracked a range of safety outcomes over an average follow-up of nearly a year, and misuse and abuse were among the events specifically monitored.¹⁵ This is notable because the study was conducted partly to support switching diclofenac gel to over-the-counter status, meaning the researchers were actively looking for any abuse signal. The very fact that regulators are moving topical diclofenac in the direction of less restriction, not more, tells you how far this drug is from controlled-substance territory.

What About Dependence and Withdrawal?

People who take diclofenac regularly for chronic conditions like rheumatoid arthritis or osteoarthritis sometimes notice that their pain returns when they stop. This is not withdrawal in the way opioid withdrawal works. With opioids, the body’s own pain-regulation systems become suppressed, so stopping the drug produces a syndrome of sweating, nausea, muscle cramps, anxiety, and intense cravings that can last weeks. With diclofenac, what you feel when you stop is simply the return of the underlying inflammation and pain that the drug was suppressing. The pain comes back because the disease is still there, not because your nervous system has been rewired by the drug.

That said, some patients do become psychologically reliant on NSAIDs in the sense that they feel they cannot function without them, particularly people with chronic pain who have found diclofenac to be the only thing that brings adequate relief. This is a reasonable human response to effective treatment, not pharmacological addiction. Your doctor might advise tapering off if you have been on high doses for a long time, but that is usually about managing rebound inflammation smoothly, not about preventing a withdrawal syndrome.

An Unexpected Environmental Impact

One of the strangest chapters in diclofenac’s history has nothing to do with human medicine. In the 1990s, populations of three vulture species across South Asia collapsed catastrophically. Researchers eventually traced the cause to veterinary diclofenac. When livestock were treated with the drug shortly before death, vultures feeding on the carcasses ingested enough diclofenac to cause kidney damage, visceral gout, and death.¹⁶ The Indian government banned veterinary diclofenac in 2006, and monitoring afterward showed that the rate of vulture decline slowed substantially once carcass contamination levels dropped.¹⁷

The environmental story extends to water systems as well. Diclofenac is one of the most frequently detected pharmaceuticals in surface water and groundwater worldwide. Monitoring across European countries has found it in groundwater at concentrations ranging from about 1 nanogram per liter in France up to 5,300 nanograms per liter in Germany.¹⁸ In Asia and Africa, surface water concentrations can exceed 8,000 nanograms per liter, driven by wastewater discharge and livestock runoff.¹⁹ At these concentrations, diclofenac can cause oxidative stress and acute toxicity in aquatic organisms. The European Union placed diclofenac on a watch list of emerging water pollutants, though it was later removed after sufficient monitoring data were gathered. The environmental footprint of a widely used, non-controlled NSAID turns out to be a bigger regulatory headache in some ways than many actual controlled substances, which are produced in far smaller quantities.

Prescription Versus Over-the-Counter Status

The prescription requirement for oral diclofenac sometimes feeds the misconception that it must be controlled. In practice, “prescription-only” and “controlled substance” are two completely different regulatory categories. Plenty of non-addictive medications require prescriptions simply because they carry risks that warrant medical supervision. Antibiotics, blood pressure drugs, and corticosteroids all need prescriptions without being anywhere near a controlled-substance schedule. Oral diclofenac sits in the same bucket: you need a prescription because of the cardiovascular and gastrointestinal risks, not because anyone is worried you will abuse it.

Topical diclofenac occupies a middle ground that varies by country. In the US, the 1% gel is prescription-only, but regulatory efforts are underway to make it available over the counter. In the UK and much of Europe, lower-strength topical diclofenac products have been over the counter for years. The trend is clearly toward less restriction for topical forms, reflecting the dramatically lower systemic exposure they produce and the absence of any abuse signal. If diclofenac were even remotely close to being a controlled substance, the regulatory trajectory would be moving in the opposite direction.